Reuters logo
BRIEF-OPKO health provides update on hGH-CTP clinical programs
December 30, 2016 / 1:47 PM / a year ago

BRIEF-OPKO health provides update on hGH-CTP clinical programs

Dec 30 (Reuters) - OPKO Health Inc :

* Initiated global pediatric phase 3 clinical study of hGH-CTP in growth hormone deficient children

* OPKO Health - on primary endpoint of change in trunk fat mass from baseline to 26 weeks,was no statistical difference between hGH-CTP and placebo

* As a result, OPKO is undertaking further review of study population as promptly as possible

* OPKO Health Inc - commenced data analysis of phase 3 clinical study of hGH-CTP in growth hormone deficient adults

* OPKO Health Inc - after unblinding study, OPKO identified one or more outliers that may have affected primary outcome

* OPKO Health Inc says OPKO is responsible for conducting clinical program and Pfizer is responsible for registering and commercializing product

* OPKO Health - under agreement, OPKO is responsible for conducting clinical program and Pfizer is responsible for registering,commercializing product

* OPKO Health provides update on hGH-CTP clinical programs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below